Login/Sign Up
₹8999
(Inclusive of all Taxes)
Get Free delivery (₹99) with
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's is indicated for weight management when used together with a reduced-calorie diet and increased physical activity in individuals with obesity. It also helps to lower the risk of serious heart-related problems, such as heart attack and stroke, in people with obesity or overweight and established heart disease.
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone involved in appetite regulation. It works by slowing the emptying of food from the stomach, increasing feelings of fullness, and reducing hunger, which helps lower calorie intake and support weight management. It also helps the body regulate blood sugar levels and supports overall metabolic health.
Additionally, by supporting weight loss and improving metabolic health, Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's may help lower the risk of serious heart-related problems, such as heart attack and stroke, in people who are overweight or obese and have heart disease.
In some cases, Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's may cause side effects such as nausea, vomiting, diarrhoea, constipation, abdominal discomfort, dizziness, or altered taste. Talk to your doctor if the side effects persist or worsen.
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's is available in a pre-filled multi-dose pen that allows flexible dosing. It features an easy-to-use dialer for accurate dose delivery and is designed for convenient self-administration. Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's is not recommended for use in children, during pregnancy, or while breastfeeding.
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's is used to treat various medical conditions. The detailed uses are as follows:
Caution
You are recommended to avoid alcohol consumption while taking Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's. It could lead to increased adverse events.
Unsafe
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's should not be used during pregnancy as there is a potential risk of harm to the unborn baby. Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's is not recommended for women who are pregnant, planning to conceive soon, or not using reliable contraception during therapy.
Unsafe
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's is not recommended during breastfeeding as its safety is not established.
Caution
Generally does not impair ability to drive; however, dizziness or low blood sugar (if combined with other drugs) may affect alertness.
Caution
Inform your doctor before receiving Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's if you have a pre-existing or a history of liver disease. Your doctor will prescribe only if the benefits outweigh the risks.
Caution
Inform your doctor before receiving Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's if you have a pre-existing or a history of kidney disease. Your doctor will prescribe only if the benefits outweigh the risks.
Consult your doctor
It is not recommended for use in children under 18 years of age, as the safety and efficacy have not been established.
Safe if prescribed
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's is used in patients with heart disease to help reduce the risk of major adverse events such as heart attack and stroke. However, people who have an irregular heartbeat or a very fast heart rate may need closer monitoring during treatment to make sure the medicine is safe and working properly.
Caution
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's should be used with caution in elderly patients, as it may be associated with a higher risk of fractures.
Have a query?
Keep Refrigerated. Do not freeze.Prepaid payment required.
Drug-Drug Interactions: Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's potentially interacts with certain medications used to treat certain cancers (e.g., bexarotene, capivasertib), certain general anaesthetics (e.g., desflurane, enflurane, etomidate, fospropofol, halothane, isoflurane, ketamine), antibiotics (e.g., gatifloxacin), certain insulin or sulfonylureas (e.g., glimepiride, glyburide) and certain GLP‑1 receptor agonists or similar weight-loss medications (e.g., liraglutide, tirzepatide).
Drug-Food Interactions: There are no significant food restrictions with Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's. However, limit alcohol intake as it can worsen nausea and vomiting and may increase the risk of low blood sugar, particularly if you are using other diabetes medicines.
Drug-Disease Interactions: If you have a history of suicidal behaviour and ideation, thyroid cancer, hypoglycemia, pancreatitis, retinopathy and GI adverse reactions. Inform your doctor before starting treatment with Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's. These conditions may require close monitoring or adjustments to your therapy.
Login/Sign Up
Login/Sign Up
Alkem Laboratories Ltd
₹3500
(₹3500.0 per unit)
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's is used for weight management in people with obesity when combined with a reduced-calorie diet and increased physical activity. It may also help lower the risk of serious heart-related problems, such as heart attack and stroke, in people who are overweight or obese and have heart disease.
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's works by acting like a natural hormone in the body that helps control appetite. It helps you feel full for longer, reduces hunger, and slows down the movement of food from the stomach. This can help you eat less and manage your weight more effectively. It also helps the body regulate blood sugar levels. By supporting weight loss and improving metabolic health, Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's may help lower the risk of serious heart-related problems, such as heart attack and stroke, in certain individuals with heart disease.
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's may cause side effects such as nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue, upset stomach, dizziness, bloating, belching, low blood sugar (in people with type 2 diabetes), gas, gastroenteritis (stomach flu), heartburn, runny nose, and sore throat. Side effects may vary from person to person depending on individual factors. Consult your doctor if any side effects persist, worsen, or become bothersome.
Pancreatitis (inflammation of the pancreas) is a possible side effect of Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's. Stop using Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's and contact your healthcare provider immediately if you develop severe, persistent stomach pain, with or without nausea or vomiting. The pain may also spread from your abdomen to your back.
Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's may increase the risk of low blood sugar, especially in people with type 2 diabetes who also take insulin or certain diabetes medicines such as sulfonylureas. Checking your blood sugar levels before starting Poviztra 2.4mg/3ml Flextouch Prefilled Pen Injection Combipack 1's and during treatment is recommended. Symptoms of low blood sugar may include dizziness, sweating, shakiness, blurred vision, weakness, hunger, headache, anxiety, irritability, confusion, drowsiness, a fast heartbeat, slurred speech, or feeling jittery. If you experience these symptoms, contact your healthcare provider for advice on managing low blood sugar.
Disclaimer

RX